Hydrogel Corneal Inlay Promising in Pseudophakic Presbyopia
24 April 2015
A transparent hydrogel corneal inlay is a novel way to correct the vision of patients with pseudophakic presbyopia, a new study shows.
It pays to seek EMA advice, analysis shows; the earlier, the better
24 April 2015
Taking the EMA's advice on trial design is both voluntary and costly, but a new analysis shows that doing so vastly increases the likelihood of getting marketing approval.
Watch out, Big Pharma: A Teva-Mylan combo would remake the industry Top 10
24 April 2015
As of 2014, Teva ($TEVA) is in the No. 11 spot on the list of pharma's top revenue generators. But if it gets its way and lands a deal for rival generics maker Mylan ($MYL), just how much will it be moving up the charts?
Small European study highlights promise of gene therapy for rare immune disease
24 April 2015
A biotech with deep roots in the European gene therapy field has successfully tested a new approach to creating a personalized gene therapy for a rare disorder of the immune system.
FDA issues new guidelines on acceptance of data from overseas clinical trials
23 April 2015
The FDA issued guidelines on its acceptance of medical device clinical data from overseas studies in a just-issued draft guidance, saying the "increasing globalization of clinical trials presents challenges to both U.S. and foreign regulators."
FDA, industry scrambling to clarify or design new regs covering lab-developed tests
23 April 2015
Science is rapidly shaping the landscape of the diagnostics industry, from the research into genetics and new materials like graphene, to the regulatory science practiced at the FDA.
23 April 2015
Grappling with regulatory delays, several Indian pharma companies are looking to set up manufacturing facilities outside the country.
China steps up decentralized drug industry regulation, market prices push
23 April 2015
China authorities at the highest level are acting on legislation that would, among other things, decentralize drug industry regulation and free some price controls.
22 April 2015
Сlearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the purchase and acquisition of iScience Interventional Corporation’s patent portfolio covering drug delivery to the suprachoroidal space (SCS).
Australia's Brandon Capital stakes a claim as Asian biotech booster with A$200M fund
22 April 2015
The buzz around biotech in Asia has centered on friends and family bootstrap operations in China, local investor support in Taiwan and onto more formal state-backed incubation efforts in Japan, South Korea and Singapore along with boutique venture capital firms and investment arms of multinationals, such as Eli Lilly Ventures.
06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
87% of cancer patients give positive ratings for medical care quality
18 September 2024
The Russian market of fillers and biorevitalizers grew by 21% in the first half of 2024
18 September 2024
Pharma’s Patient Reach Problem: Billions Still Left Behind
17 September 2024
17 September 2024